Skelton Matthew R, O'Neil Bert
Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Clin Adv Hematol Oncol. 2008 Mar;6(3):209-18.
Hepatocellular carcinoma (HCC) remains a highly lethal disease that is resistant to traditional cytotoxic chemotherapy. The last 30 years of chemotherapy clinical trials for advanced HCC have repeatedly failed to demonstrate any survival benefit for a long list of drugs. However a survival advantage was recently established for sorafenib, instituting a new standard of care for unresectable HCC. Here we review recent and ongoing studies of new therapeutic agents for HCC, including the small-molecule tyrosine kinase inhibitors, monoclonal antibodies, and combinations of these drugs.
肝细胞癌（HCC）仍然是一种对传统细胞毒性化疗耐药的高致死性疾病。过去30年针对晚期HCC的化疗临床试验反复表明，众多药物均未能显示出任何生存获益。然而，最近索拉非尼确立了生存优势，为不可切除的HCC制定了新的治疗标准。在此，我们综述了近期及正在进行的针对HCC的新型治疗药物的研究，包括小分子酪氨酸激酶抑制剂、单克隆抗体以及这些药物的联合应用。
